O-methyl reboxetine: Clinical Trials

13 trials of O-methyl reboxetine, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 completed, 6 terminated, 1 withdrawn. 7 Phase 2, 3 Phase 3, 1 Not applicable.

By phase and status

Phase	Trials	Status
Phase 2	7	Terminated 4, Completed 3
Phase 3	3	Terminated 2, Completed 1
Not applicable	1	Completed 1

Follow O-methyl reboxetine: new trials by email Literature Review of O-methyl reboxetine trials Research Report on O-methyl reboxetine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand Norepinephrine Transporter (NET) ligand - Hypoglycemia		Completed	Yale University	9	2011-06-01	2020-03-06
Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia [S,S]-Reboxetine - Fibromyalgia	Phase 3	Terminated	Pfizer	390	2008-05-01	2019-12-17
A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia. [S,S]-Reboxetine, Placebo - Fibromyalgia	Phase 3	Completed	Pfizer	1129	2007-12-01	2019-12-12
A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy. Placebo, [S,S]-Reboxetine - Diabetic Neuropathies	Phase 2	Terminated	Pfizer	330	2007-12-01	2019-12-13
Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia [S,S]-reboxetine - Fibromyalgia	Phase 3	Terminated	Pfizer	500	2007-10-20	2019-12-13
Norepinephrine Transporter Imaging in Addiction Disorders (S,S)-[11C]MRB - Obesity, Alcohol Dependence		Withdrawn	Yale University		2007-07-01	2023-03-02
Evaluation of A Novel Methodology in the Assessment of Urethral Function Using [S,S]-Reboxetine in Healthy Volunteers [S,S]-Reboxetine - Healthy	Not applicable	Completed	Pfizer	12	2007-05-01	2011-06-01
[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain. [S,S]-Reboxetine - Pain	Phase 2	Terminated	Pfizer	600	2006-11-01	2007-11-08
A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia [S,S]-Reboxetine - Pain	Phase 2	Completed	Pfizer	246	2006-08-01	2013-05-15
[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy. [S,S]-Reboxetine, Any - Pain	Phase 2	Terminated	Pfizer	136	2006-07-01	2011-06-01
A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain. [S,S]-Reboxetine - Pain	Phase 2	Terminated	Pfizer	112	2006-07-01	2011-04-07
[S,S]-Reboxetine Dose-Range Finding Trial [S,S]-Reboxetine - Pain	Phase 2	Completed	Pfizer	280	2006-03-01	2011-06-08
Study of [S,S]-Reboxetine in Patients With Postherpetic Neuralgia, Who Are Gabapentin Treatment Failures [S,S]-Reboxetine - Pain	Phase 2	Completed	Pfizer	184	2003-12-01	2006-08-08

Conditions studied

Pain (6) · Fibromyalgia (3) · Alcoholism (1) · Diabetic Neuropathies (1) · Hypoglycemia (1) · Obesity (1)

Countries

United States (11) · Canada (5) · South Africa (3) · Sweden (3) · United Kingdom (3) · Argentina (2) · Croatia (2) · Czechia (2) · Finland (2) · Germany (2) · India (2) · Netherlands (2) · Poland (2) · Spain (2) · Belgium (1)

Top investigators

Marc N Potenza, MD, PhD (1) · Renata Belfort De Aguiar, MD (1)

Results publications

PMID 20974319, PMID 22275142, PMID 29590401

NIH funding

R01DK020495 (1), RL1AA017540 (1)